Company Filing History:
2 out of 167 
1 out of 4,179 
1 out of 139 
Years Active: 2012-2016
Title: Ralf Loebbert: Innovator in Antibody Research
Introduction
Ralf Loebbert is a notable inventor based in Speyer, Germany. He has made significant contributions to the field of antibody research, particularly in relation to the receptor of advanced glycation end products (RAGE). With a total of 3 patents, his work has implications for treating various diseases associated with RAGE.
Latest Patents
One of his latest patents is focused on "Antibodies to receptor of advanced glycation end products (RAGE) and uses thereof." This application relates to isolated proteins, specifically monoclonal antibodies that bind to the RAGE protein. These antibodies are designed to inhibit the binding of RAGE to its ligands, which can be beneficial in treating diseases characterized by pathophysiological ligands of RAGE, such as misfolded proteins like amyloid β and advanced glycation end-products. Another significant patent is titled "AGER-peptides and use thereof." This invention identifies and utilizes domains from the N terminus of the receptor for Advanced Glycation End Products (AGER). These domains are crucial for AGER self-association and heteromerization with other proteins, making them valuable for various applications, including immunization and diagnostic purposes.
Career Highlights
Ralf Loebbert has worked with prominent companies in the pharmaceutical industry, including AbbVie Deutschland GmbH & Co. KG and Abbott Laboratories Corporation. His experience in these organizations has contributed to his expertise in antibody development and research.
Collaborations
Throughout his career, Ralf has collaborated with notable colleagues such as Martin Schmidt and Ulrich Ebert. These partnerships have likely enhanced his research and innovation in the field.
Conclusion
Ralf Loebbert's contributions to antibody research and his innovative patents highlight his role as a significant inventor in the scientific community. His work continues to pave the way for advancements in medical treatments related to RAGE.